Wanbury: Wanbury Skin Health Limited (Subsidiary of Wanbury Limited) Launches its berrysoftTM baby Product Range…
Wanbury (WANBURY) filed a disclosure titled "Wanbury Skin Health Limited (Subsidiary of Wanbury Limited) Launches its berrysoftTM baby Product Range Across Multiple States in India, Marks Strategic Entry in The Paediatric…". The company is valued at about…
What happened
Wanbury (WANBURY) filed a disclosure with the exchanges on 12 October 2026 at 01:28 PM titled "Wanbury Skin Health Limited (Subsidiary of Wanbury Limited) Launches its berrysoftTM baby Product Range Across Multiple States in India, Marks Strategic Entry in The Paediatric…".
Company snapshot
Wanbury is a micro-cap company, with a market value of about ₹691 crore.
The stock last traded at ₹197.8, against a 52-week range of ₹161.5–₹358.9 (44.9% below the high).
Before this filing the shares had moved −18.6% over the month and −41.5% over three months. Average daily turnover over the last 20 sessions was about ₹6.37 crore.
Promoters held 43.02% at the end of Q1 FY27; 86.69% of promoter shares were pledged. Foreign institutions owned 0.89% and domestic institutions 0.06%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 163 | 13.5 | 4.12 |
| Q2 FY26 | 160 | 15.2 | 4.58 |
| Q3 FY26 | 162 | 15.8 | 4.52 |
| Q4 FY26 | 165 | 21.7 | 7.33 |
| Q1 FY27 | 166 | 3.2 | 0.93 |
What history shows
This is not the company's first corporate update disclosure: BCEIE has 9 earlier filings of this kind on record since May 2026.
After those filings, the stock fell 1.8% on average the next trading day and was up 0.9% on average after five days (7 filings with price data).
Market-wide, 157 corporate update filings with an impact score of 50 or more saw an average next-day move of −0.7%, with 35% rising.
Past reactions describe what happened before; they are not a forecast.
| Date | Filing | Next day | 5 days |
|---|---|---|---|
| 13 Aug 2026 | Corporate update | −0.5% | +2.2% |
| 11 Aug 2026 | Press Release | −1.3% | +6.0% |
| 22 Jul 2026 | Corporate update | −2.7% | −9.6% |
| 10 Jun 2026 | Corporate update | −3.7% | +0.8% |
In the news
Recent coverage elsewhere (links open the original publisher):
- Wanbury Limited (WANBURY.NS) Holds Near ₹197.72 as Pharma Stock Consolidates Below Resistance - Risk Reversal
- WANBURY Share Price Today: Price Rise and Valuation View
- Wanbury NSE:WANBURY Trading Window Closure October 2026
- Wanbury Ltd files new Drug Master File in South Africa for Tramadol HCl API
- Wanbury Share Price Today: Fundamentals and Sector View
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.